We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+10.65%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.58B
AUM Growth
-$133M
Cap. Flow
-$75.4M
Cap. Flow %
-1.64%
Top 10 Hldgs %
23.53%
Holding
172
New
18
Increased
60
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$102M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$50.7M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$48.4M
4
CGEM icon
Cullinan Oncology
CGEM
+$43.7M
5
AZN icon
AstraZeneca
AZN
+$32.7M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$58.7M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$47.9M
3
UNH icon
UnitedHealth
UNH
+$45M
4
CNC icon
Centene
CNC
+$43.8M
5
IMVT icon
Immunovant
IMVT
+$41.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Consumer Staples 1.75%
3 Industrials 0.62%
4 Financials 0.12%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRA
76
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$17.5M 0.38%
1,017,358
+450,000
+79% +$7.13M
GMDA
77
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$17M 0.37%
2,100,300
+6,300
+0.3% +$57.8K
INZY
78
DELISTED
Inozyme Pharma
INZY
$16.4M 0.36%
827,900
-2,646
-0.3% -$58.4K
PRLD icon
79
Prelude Therapeutics
PRLD
$385M
$16.4M 0.36%
378,195
+17,832
+5% +$1.18M
DVAX
80
DELISTED
Dynavax Technologies
DVAX
$16.3M 0.36%
1,658,520
+9,100
+0.6% +$75K
RIGL icon
81
Rigel Pharmaceuticals
RIGL
$778M
$16.2M 0.35%
474,200
-89
-0% -$3.52K
NKTX icon
82
Nkarta
NKTX
$176M
$16.2M 0.35%
491,848
-49,152
-9% -$2.35M
MREO
83
Mereo BioPharma
MREO
$43.5M
$15.1M 0.33%
+4,494,869
New +$15.9M
AKRO
84
DELISTED
Akero Therapeutics
AKRO
$15.1M 0.33%
521,171
+5,800
+1% +$176K
EPIX
85
DELISTED
ESSA Pharma
EPIX
$14.6M 0.32%
+503,035
New +$11.7M
LONA
86
LeonaBio Inc
LONA
$70.5M
$14.5M 0.32%
78,820
-7,270
-8% -$1.6M
OLK
87
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$14.4M 0.31%
+400,000
New +$13.5M
SPRO icon
88
Spero Therapeutics
SPRO
$71.2M
$14.2M 0.31%
965,928
-269,072
-22% -$4.74M
TBPH icon
89
Theravance Biopharma
TBPH
$876M
$13.9M 0.3%
682,600
+4,400
+0.6% +$83.6K
CERE
90
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$13.8M 0.3%
1,005,100
+6,100
+0.6% +$89.3K
APLT
91
DELISTED
Applied Therapeutics
APLT
$13.2M 0.29%
701,680
+65,843
+10% +$1.42M
TGTX icon
92
TG Therapeutics
TGTX
$7.52B
$12.8M 0.28%
266,520
-222,480
-45% -$10.7M
RYTM icon
93
Rhythm Pharmaceuticals
RYTM
$7.95B
$12.7M 0.28%
599,280
+108,941
+22% +$3.16M
LKFT
94
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.76B
$12.7M 0.28%
165,000
– –
MGNX icon
95
MacroGenics
MGNX
$259M
$12.5M 0.27%
393,479
+83,969
+27% +$2.04M
SYRE icon
96
Spyre Therapeutics
SYRE
$9.29B
$12.5M 0.27%
63,092
-108
-0.2% -$20.7K
INNV icon
97
InnovAge Holding
INNV
$1.48B
$12.3M 0.27%
+475,000
New +$11.7M
PRTK
98
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$11.9M 0.26%
1,684,714
+4,100
+0.2% +$29.5K
BAX icon
99
Baxter International
BAX
$14.4B
$11.8M 0.26%
140,000
-161,000
-53% -$12.8M
ANAB icon
100
AnaptysBio
ANAB
$1.64B
$11.5M 0.25%
535,232
+225,819
+73% +$5.7M
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Rock Springs Capital Management held 172 positions worth $4.58B, down 2.8% from $4.72B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management's Q1 2021 filing shows 18 new, 60 increased, 32 reduced and 21 closed positions. Its largest new stake was Immunocore: 2,292,285 shares worth $97.6M. The largest sale was Neurocrine Biosciences, an estimated $58.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2021 buy was Immunocore: 2,292,285 shares worth $97.6M.
  • Rock Springs Capital Management added most to Five Prime Therapeutics, Inc. in Q1 2021, an estimated $48.4M increase.
  • Rock Springs Capital Management's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $58.7M.
  • Rock Springs Capital Management fully exited Alexion Pharmaceuticals in Q1 2021, selling an estimated $47.9M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $4.58B portfolio in Q1 2021.
  • Rock Springs Capital Management opened 18 new positions and closed 21 in Q1 2021.
  • Rock Springs Capital Management's portfolio value fell 2.8% quarter-over-quarter to $4.58B.

Based on Rock Springs Capital Management's 13F filing for Q1 2021, filed 17 May 2021.